Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy.
Montico B, Colizzi F, Giurato G, Rizzo A, Salvati A, Baboci L, Benedetti D, Pivetta E, Covre A, Bo MD, Weisz A, Steffan A, Maio M, Sigalotti L, Fratta E.
Montico B, et al. Among authors: covre a.
Cell Death Dis. 2020 May 22;11(5):392. doi: 10.1038/s41419-020-2585-y.
Cell Death Dis. 2020.
PMID: 32444628
Free PMC article.